| Literature DB >> 26835198 |
Benjamin D Elder1, Eric W Sankey1, C Rory Goodwin1, Thomas A Kosztowski1, Sheng-Fu L Lo1, Ali Bydon1, Jean-Paul Wolinsky1, Ziya L Gokaslan1, Timothy F Witham1, Daniel M Sciubba1.
Abstract
Study Design Retrospective review. Objective To describe the surgical outcomes in patients with high preoperative Spinal Instability Neoplastic Score (SINS) secondary to spinal giant cell tumors (GCT) and evaluate the impact of en bloc versus intralesional resection and preoperative embolization on postoperative outcomes. Methods A retrospective analysis was performed on 14 patients with GCTs of the spine who underwent surgical treatment prior to the use of denosumab. A univariate analysis was performed comparing the patient demographics, perioperative characteristics, and surgical outcomes between patients who underwent en bloc marginal (n = 6) compared with those who had intralesional (n = 8) resection. Results Six patients underwent en bloc resections and eight underwent intralesional resection. Preoperative embolization was performed in eight patients. All patients were alive at last follow-up, with a mean follow-up length of 43 months. Patients who underwent en bloc resection had longer average operative times (p = 0.0251), higher rates of early (p = 0.0182) and late (p = 0.0389) complications, and a higher rate of surgical revision (p = 0.0120). There was a 25% (2/8 patients) local recurrence rate for intralesional resection and a 0% (0/6 patients) local recurrence rate for en bloc resection (p = 0.0929). Conclusions Surgical excision of spinal GCTs causing significant instability, assessed by SINS, is associated with high intraoperative blood loss despite embolization and independent of resection method. En bloc resection requires a longer operative duration and is associated with a higher risk of complications when compared with intralesional resection. However, the increased morbidity associated with en bloc resection may be justified as it may minimize the risk of local recurrence.Entities:
Keywords: Enneking class; SINS score; embolization; en bloc; giant cell tumor; intralesional; spine
Year: 2015 PMID: 26835198 PMCID: PMC4733366 DOI: 10.1055/s-0035-1555657
Source DB: PubMed Journal: Global Spine J ISSN: 2192-5682
Individual patient treatment summaries
| Patient no. | Age (y) | Sex | Tumor location | SINS | Prior treatment | Surgical approach | Instrumented levels | Complications | Follow-up duration (mo) | Recurrence | Mortality by LFU | Sarcoma transformation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 29 | M | T12 | 11 | Embo | En bloc marginal | T10–L2 | Large (2L) pleural effusion, rod fracture | 84 | No | No | No |
| 2 | 31 | F | L4 | 9 | None | En bloc marginal | L4 cage, L2–pelvis | None | 30 | No | No | No |
| 3 | 58 | F | L4–L5 | 14 | Embo | En bloc marginal | L4–L5 cage/plate, L2–pelvis | Wound dehiscence (×2), CSF leak, delayed hardware failure | 51 | No | No | No |
| 4 | 35 | F | L5 | 11 | Embo | En bloc marginal | L5 cage/plate, L3–pelvis | Wound dehiscence | 103 | No | No | No |
| 5 | 42 | M | S1–S3 | 10 | None | En bloc marginal | L3–pelvis | Small bowel perforation, peritonitis, hypotension requiring vasopressors | 51 | No | No | No |
| 6 | 45 | F | S1–S3 | 10 | Embo | En bloc marginal | L4–pelvis | None | 0.5 | No | No | No |
| 7 | 62 | F | C4 | 15 | None | Intralesional | C4 cage, C3–C5 plate, C3–C6 posterior cervical fusion | None | 3 | Yes, 4 mo after surgery | No | No |
| 8 | 31 | F | C6 | 9 | Embo | Intralesional | C5–C7 plate with structural allograft | None | 21 | No | No | No |
| 9 | 64 | F | T11 | 11 | T10–T12 hemilaminectomy with biopsy | Intralesional | T11 cage, T8–L1 | Durotomy, pleural effusion, PE/DVT, superficial wound dehiscence | 1.5 | No | No | No |
| 10 | 47 | M | L5 | 12 | Open biopsy | Intralesional | L5 PMMA VBR, L4–S1 | None | 79 | No | No | No |
| 11 | 29 | M | S1–S2 | 10 | Embo | Intralesional | L3–pelvis | None | 0.5 | No | No | No |
| 12 | 21 | F | S1–S3 | 8 | None | Intralesional | L3–pelvis | None | 7 | No | No | No |
| 13 | 26 | M | S1–S3 | 10 | Embo | Intralesional | L3–pelvis | None | 85 | No | No | No |
| 14 | 39 | M | S2–S3 | 6 | Embo | Intralesional | None | None | 81 | Yes, 6 and 9 mo after surgery | No | No |
Abbreviations: CSF, cerebrospinal fluid; DVT, deep venous thrombosis; Embo, embolization; LFU, last follow-up; PE, pulmonary embolism; PMMA, polymethyl methacrylate; SINS, Spinal Instability Neoplastic Score; VBR, vertebral body replacement.
Baseline demographic information and preoperative characteristics
| Characteristics | All patients ( | En bloc ( | Intralesional ( |
|
|---|---|---|---|---|
| Patient characteristics | ||||
| Age at diagnosis, y (SEM) | 40 (4) | 40 (4) | 40 (6) | 0.9382 |
| Sex, female, | 8 (57) | 4 (67) | 4 (50) | 0.5329 |
| Symptoms/signs at presentation, | ||||
| Back pain | 13 (93) | 6 (100) | 7 (88) | 0.3688 |
| Myelopathy | 3 (21) | 0 (0) | 3 (38) | 0.0906 |
| Cauda equina | 4 (29) | 2 (33) | 2 (25) | 0.7327 |
| Duration of preoperative symptoms, mo (SEM) | 10 (3) | 8 (3) | 13 (5) | 0.4315 |
| Preoperative Frankel class | 0.2801 | |||
| D | 7 (50) | 2 (33) | 5 (63) | |
| E | 7 (50) | 4 (67) | 3 (38) | |
| History of spine tumor surgery, | 1 (7) | 0 (0) | 1 (13) | 0.3688 |
| History of chemotherapy, | 1 (7) | 1 (17) | 0 (0) | 0.2308 |
| History of radiotherapy, | 0 (0) | 0 (0) | 0 (0) | – |
| Preoperative embolization, | 8 (57) | 4 (67) | 4 (50) | 0.5329 |
| Tumor characteristics | ||||
| Spine level, | ||||
| Cervical | 2 (14) | 0 (0) | 2 (25) | 0.1859 |
| Thoracic | 2 (14) | 1 (17) | 1 (13) | 0.8255 |
| Lumbar | 4 (29) | 3 (50) | 1 (13) | 0.1243 |
| Sacral | 6 (43) | 2 (33) | 4 (50) | 0.5329 |
| Pathologic fracture, | 6 (43) | 2 (33) | 4 (50) | 0.5329 |
| Preoperative SINS score, mean (SEM) | 10 (1) | 11 (1) | 10 (1) | 0.5855 |
| Enneking classification stage | 0.8721 | |||
| II | 5 (36) | 2 (33) | 3 (38) | |
| III | 9 (64) | 4 (67) | 5 (63) | |
| Tumor volume, cm3 (SEM) | 81.7 (45.2) | 142.1 (104.2) | 36.3 (11.8) | 0.2626 |
Abbreviations: SINS, Spinal Instability Neoplastic Score; SEM, standard error of the mean.
Operative characteristics
| Perioperative characteristics | All patients ( | En bloc ( | Intralesional ( |
|
|---|---|---|---|---|
| Surgical approach, | ||||
| Anterior | 1 (7) | 0 (0) | 1 (13) | – |
| Posterior | 7 (50) | 2 (33) | 5 (63) | – |
| Anterior-posterior | 2 (14) | 1 (17) | 1 (13) | – |
| Posterior-anterior | 4 (29) | 3 (50) | 1 (13) | – |
| Staged operation, | 4 (29) | 3 (50)) | 1 (13) | – |
| Instrumented reconstruction, | 13 (93) | 6 (100) | 7 (88) | – |
| Nerve root sacrifice, | 2 (14) | 2 (33) | 0 (0) | – |
| Intraoperative blood loss, cm3 (SEM) | 2,885 (756) | 3,663 (1516) | 2,367 (817) | 0.2692 |
| Required blood transfusion, | 12 (86) | 6 (100) | 6 (75) | 0.0929 |
| Total amount of transfusion, U (SEM) | 4 (1) | 5 (1) | 2 (1) | 0.0587 |
| Operative duration, h (SEM) | 9.9 (0.8) | 11.6 (1.1) | 8.5 (0.9) | 0.0251 |
Abbreviation: SEM, standard error of the mean.
Surgical outcomes
| Outcome variable | All patients ( | En bloc ( | Intralesional ( |
|
|---|---|---|---|---|
| Operative complications, | ||||
| Early complication, | 5 (31) | 4 (67) | 1 (13) | 0.0182 |
| Late complication, | 2 (14) | 2 (33) | 0 (0) | 0.0389 |
| Length of hospital stay, d (SEM) | 13 (3) | 16 (5) | 11 (3) | 0.1981 |
| Surgical revision, | 3 (21) | 3 (50) | 0 (0) | 0.0120 |
| Local recurrence | 2 (14) | 0 (0) | 2 (25) | 0.0929 |
| Adjuvant therapies, | ||||
| Postoperative chemotherapy | 0 (0) | 0 (0) | 0 (0) | – |
| Postoperative radiation | 2 (14) | 0 (0) | 2 (25) | 0.0929 |
| Neurologic status at LFU, | 0.0929 | |||
| Intact | 9 (64) | 5 (83) | 4 (50) | |
| Symptomatic | 5 (36) | 1 (17) | 4 (50) | |
| Residual tumor at LFU, | 2 (14) | 0 (0) | 2 (25) | 0.0929 |
| Duration of follow-up, mo (SEM) | 43 (10) | 53 (15) | 35 (14) | 0.1945 |
Abbreviations: LFU, last follow-up; SEM, standard error of the mean.
Early versus late complications were stratified by complications that occurred <30 days perioperatively or >30 days postoperatively, respectively.
Fig. 1(a) Preoperative sagittal and (b) coronal nonenhanced computed tomography (CT) scans demonstrating 13.3 × 8.5-cm osteolytic S2–S4 sacral mass with invasion of the sacral foramina and anterior displacement of the sigmoid colon and bladder. (c) Preoperative sagittal T2-weighted magnetic resonance imaging (MRI) demonstrating heterogeneous-appearing mass arising from the sacrum. (d) Preoperative axial gadolinium-enhanced T1-weighted MRI demonstrating sacral mass extending into the pelvis and abutting the rectum. Postoperative (e) lateral and (f) anteroposterior radiographs demonstrating L3–pelvis instrumentation. Postoperative coronal nonenhanced CT scan demonstrating (g) instrumentation and (h) extent of en bloc sacral resection. (i) Postoperative sagittal T2-weighted MRI demonstrating extent of tumor resection.